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Public Health Dilemmas Concerning
a Two-year-old Hepatitis-B Carrier
As a public health professional, you are notified that a
2-year-old boy in your town has been found to be a
hepatitis B virus (HBV) carrier. The boy had been
immunised (actively and passively) after birth be-
cause his mother was also a HBV-carrier. Such early
immunisation prevents transmission from mother to
child in most cases, but apparently this time it had not
worked. Further investigation revealed that the child
carried a specific genetic mutant of the virus (G145R-
HBV-mutant) which could explain why passive and
active immunisation had failed. The boy has a high
viral load. As a consequence, it is reasonable to
recommend vaccination for all close contacts.
However, several questions arise. First, the child
will probably go to a day nursery within a couple of
months. Is that acceptable, given the risks of
transmission (e.g. saliva on toys)? Should profession-
als at the nursery be informed that the boy is a HBV-
carrier? Should they take strict hygienic measures
towards the boy? Should other parents be informed
about the risk of infection? One option is to warn all
parents that a child at the nursery is a carrier, and to
offer them vaccination of their children. Such mea-
sures however may involve stigmatization of the boy.
Moreover, the fact that vaccination did not protect
this child suggests that vaccination may be less effective
in preventing infection with this specific HBV-mutant.
Hence, does it make sense to offer vaccination to other
children at the day nursery? In fact, there are reasons to
think that normal vaccination does offer immunity to
this mutant [1, 2], but not all experts agree with those
reasons [3]. How should the (limited) evidence be
weighed, and what are the implications for hygienic
measures and information disclosure at the nursery?
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